2016-08-12T13:16:35-05:00 2015-12-31 BOND BEEBE PC 4600 EAST-WEST HIGHWAY SUITE 900 BETHESDA MD 208143423 990 2015-01-01 042531031 NATIONAL FOUNDATION FOR CANCER RESEARCH % SUJUAN BA NATI 3016541250 4600 EAST-WEST HIGHWAY Suite 525 BETHESDA MD 20814 FRANKLIN C SALISBURY JR CEO 3016541250 2016-08-12 true JOEL C SUSCO P00189961 3012726000 2016-08-12 2015 2016-12-15 16:53:06Z FRANKLIN C SALISBURY JR 4600 EAST-WEST HWY SUITE 525 BETHESDA MD 20814 16981413 false 5582 X WWW.NFCR.ORG X 1973 MA TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. 7 7 27 100 16841 10194 14884024 13729474 0 0 528158 291958 339150 280368 15751332 14301800 4380001 2494883 0 0 2056034 2283506 64275 45138 2654129 8304445 8331748 14804755 13155275 946577 1146525 13727385 13163238 3435282 2236940 10292103 10926298 X THE NATIONAL FOUNDATION FOR CANCER RESEARCH (NFCR) IS A LEADING PUBLIC CHARITY DEDICATED TO FUNDING CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO CANCER PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND, ULTIMATELY, CURES FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. SINCE 1973, NFCR HAS PROVIDED MORE THAN $330 MILLION IN SUPPORT OF DISCOVERY-ORIENTED CANCER RESEARCH FOCUSED ON UNDERSTANDING HOW AND WHY CELLS BECOME CANCEROUS, AND ON PUBLIC EDUCATION RELATING TO CANCER PREVENTION, DETECTION, AND TREATMENT. NFCR SCIENTISTS ARE DISCOVERING CANCER'S MOLECULAR MYSTERIES AND TRANSLATING THEIR DISCOVERIES INTO THERAPIES THAT HOLD THE HOPE FOR CURING CANCER. NFCR IS ABOUT SAVING LIVES NFCR-FUNDED RESEARCHERS ARE MAKING PROGRESS EVERY DAY IN THEIR PURSUIT OF CANCER CURES, AND THIS IS ONLY POSSIBLE WITH THE FINANCIAL SUPPORT OF MILLIONS OF DONORS NATIONWIDE. ONE STEP AT A TIME, WE ARE GETTING CLOSER TO O false false 3935593 2503248 CANCER RESEARCH - SEE SCHEDULE O 5729242 CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O 9664835 true true false false false true false false false true true false false true false true false true false false true true false true true false false true true true false false false false false false false false true false false false false true false false false true 41 0 true 27 true true true true HK false false false true true false false false false false false false X 7 7 true false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OR PA RI SC TN UT VA WA WV WI X X SUJUAN BA 3016541250 4600 EAST-WEST HIGHWAY SUITE 525 BETHESDA MD 20814 X JOSEPH F FRANLIN CHAIR 5.0 0.0 X X 0 0 0 MARK R BARAN TREASURER 2.0 0.0 X X 0 0 0 JUDITH P BARNHARD DIRECTOR 2.0 0.0 X 0 0 0 MICHAEL BURKE DIRECTOR (EFF. JAN 2015) 2.0 0.0 X 0 0 0 PADMAKUMAR KAIMAL DIRECTOR 2.0 0.0 X 0 0 0 WENDY P DENNARD DIRECTOR (EFF. JULY 2015) 2.0 0.0 X 0 0 0 EDWARD S WEST DIRECTOR (EFF. JULY 2015) 2.0 0.0 X 0 0 0 FRANKLIN C SALISBURY JR CHIEF EXECUTIVE OFFICER 40.0 2.0 X 313852 0 69338 SUJUAN BA PRESIDENT/COO 40.0 2.0 X 300778 0 65788 KWOK LEUNG CFO/SECRETARY 40.0 2.0 X 121086 0 21797 YI WANG CHIEF SCIENCE OFFICER 40.0 0.0 X 189686 0 30723 DAVID P BJORK VICE PRESIDENT OF DEVELOPMENT 40.0 0.0 X 125294 0 7965 1050696 0 195611 5 false true false REDFIELD CO 1901 HOWARD STREET OMAHA NE 68102 LABEL PRINTING 998054 CALMARK GROUP LLC 6755 S SAYRE AVE BEDFORD PARK IL 60638 MAILSHOP 883402 CP DIRECT INC 4600 A BOSTON WAY LANHAM MD 20706 PRINTING 682421 MACKAY MITCHELL ENVELOPE CO 2100 ELM ST SE MINNEAPOLIS MN 55414 ENVELOPE PRINTING 441726 KEY ACQUISITION PARTNERS 2525 RIVA ROAD STE 145 ANNAPOLIS MD 21401 LIST BROKER 320379 8 X 89904 372565 8364 13258641 614868 13729474 0 363047 363047 0 9733 9733 0 0 0 2459789 2530878 -71089 -71089 -71089 61338 372565 148735 -87397 -87397 0 0 MAILING LIST RENTALS 541800 358032 16841 341191 358032 14301800 16841 555485 1921405 1921405 25000 25000 548478 548478 0 897989 730990 140829 26170 0 1067495 690720 139843 236932 110904 67506 13006 30392 92315 59623 15780 16912 114803 81793 16404 16606 0 89222 11564 77658 40478 40478 0 45138 45138 57829 57829 498330 431086 54962 12282 21520 8415 4917 8188 257019 39473 209979 7567 416866 304845 112021 0 196169 140191 28149 27829 53372 30162 23107 103 0 65287 65287 0 0 17534 12517 2502 2515 36412 26008 5198 5206 DIRECT MAIL PROGRAMS 6335173 4301385 2033788 LOCK BOX SERVICE 166680 119094 47586 PROCESS FEES-LIST SALES & EXCH 69016 49293 19723 MAJOR GIFT 5171 5171 5670 5670 13155275 9664835 836311 2654129 X 6784492 4887483 0 1897009 1000 1000 2392061 2823984 0 0 557179 289287 0 0 0 0 0 0 0 0 452366 389623 225744 171623 56403 54121 7733013 7228623 442 442 0 0 0 0 2534921 2376158 13727385 13163238 3362100 2213578 50000 0 23182 23362 0 0 0 0 0 0 0 0 0 0 0 0 3435282 2236940 X 6915470 7548830 1266306 1418289 2110327 1959179 10292103 10926298 13727385 13163238 1146525 -512330 X false true X true false X 13091771 13288283 12996075 14884024 13729474 67989627 0 0 13091771 13288283 12996075 14884024 13729474 67989627 2140 67987487 449250 451210 302464 334775 372780 1910479 6883 7420 16841 31144 640683 695622 320737 363577 341191 2361810 72293060 0.94044 0.93670 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 500 2890 true true 7771063 3491261 -158768 3475874 7627682 7621530 3324595 142232 3317294 7771063 7363227 2824789 170917 2737403 7621530 6372438 3373522 194219 2576952 7363227 7112065 2268932 -99336 2909223 6372438 0.55720 0.25690 0.18590 false false 2464 1320 1144 223280 170303 52977 54121 AMOUNT HELD IN TRUST BY OTHERS 2376158 2376158 0 0 X 13191056 -512330 4950 -507380 13698436 603364 603364 14301800 13172821 612546 612546 12560275 595000 595000 13155275 PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS: THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. PART X, LINE 2 - FIN 48 FOOTNOTE: Accounting principles generally accepted in the United States of America require management to evaluate income tax positions taken and accrue an income tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has evaluated the income tax positions taken and concluded that as of December 31, 2015 there are no uncertain positions taken or expected to be taken that would require accrual of a liability in the consolidated financial statements. NFCR and affiliates are subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress for any tax periods. PART XI, LINE 2D - OTHER REVENUES INCLUDED ON FINANCIALS, NOT FORM 990: $4,950 - RELATED ORGANIZATIONS' REVENUES PART XI, LINE 4B - OTHER REVENUES INCLUDED ON FORM 990, NOT FINANCIALS: $603,364 - REVENUES ELIMINATED ON THE CONSOLIDATED FINANCIALS PART XII, LINE 2D - OTHER EXPENSES INCLUDED ON FINANCIALS, NOT FORM 990: $17,546 - RELATED ORGANIZATIONS' EXPENSES PART XII, LINE 4B - OTHER EXPENSES INCLUDED ON FORM 990, NOT FINANCIALS: $595,000 - INTERCOMPANY GRANTS ELIMINATED ON THE CONSOLIDATED FINANCIALS true Europe (Including Iceland and Greenland) CHEMICAL RESEARCH 30000 CHECK 30000 SEE PART V FMV East Asia and the Pacific CANCER 50000 CHECK 435500 SEE PART V FMV East Asia and the Pacific CANCER EVENT 6840 CHECK East Asia and the Pacific CANCER 550000 CHECK 4 false false false false false false PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANTS OUTSIDE USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. PART II, LINE 1(1), COLUMN H - DESCRIPTION OF NON-CASH ASSISTANCE: PROVIDED MATERIALS, CHEMICALS AND EQUIPMENT. PART II, LINE 1(2), COLUMN H - DESCRIPTION OF NON-CASH ASSISTANCE: PROVIDED MATERIALS, CHEMICALS, AND EQUIPMENT. GRANTED CONTRACTURAL RIGHT FOR THE USE OF ITS DATABASE AND SUPERCOMPUTER TIME. X X X X X X true MERKLE INC DIRECT MAIL COUNSEL false 7619604 45138 7574466 7619604 45138 7574466 AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI DC GOLF 66077 31100 34977 23470 13847 7387 DAFFODILS 90196 63835 26361 13713 2490 8400 101 277630 277630 79428 433903 372565 61338 23470 27560 2490 95215 148735 -87397 true THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 445 NORTH FIFTH ST SUITE 600 PHOENIX AZ 85004 753065445 501(c)(3) 195561 RESEARCH CONTRACTS ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 501(c)(3) 75000 46528 FMV CHEMICALS & EQUIP RESEARCH CONTRACTS BETH ISRAEL HOSPITAL 330 BROOKLINE AVE BOSTON MA 02215 042103881 501(c)(3) 70530 RESEARCH CONTRACTS CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(c)(3) 100000 RESEARCH CONTRACTS DANA-FARBER CANCER INSTITUTE 44 BINNEY ST MAIL STOP L229 BOSTON MA 02115 042263040 501(c)(3) 46600 RESEARCH CONTRACTS MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 02241 041564655 501(c)(3) 237103 RESEARCH CONTRACTS THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA CA 92037 330435954 501(c)(3) 331794 RESEARCH CONTRACTS UNIVERSITY OF TEXAS - MD ANDERSON CANCER CENTER PO BOX 4390 HOUSTON TX 77210 501(c)(3) 333429 18000 fmv chemicals & equip RESEARCH CONTRACTS UNIVERSITY OF CALIFORNIA AT SAN DIEGO PO BOX 12385 LA JOLLA CA 92093 501(c)(3) 49541 RESEARCH CONTRACTS UNIVERSITY OF COLORADO AT DENVER OFFICE OF GRANTS DENVER CO 80291 501(c)(3) 30809 RESEARCH CONTRACTS UNIVERSITY OF MARYLAND 220 ARCH ST OFFICE LEVEL 2 BALTIMORE MD 21201 501(c)(3) 46891 50000 fmv chemicals & equip RESEARCH CONTRACTS VIRGINA COMMONWEALTH UNIVERSITY PO BOX 980568 RICHMOND VA 23298 501(C)(3) 50000 10000 fmv chemicals & equip RESEARCH CONTRACTS YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(c)(3) 75049 RESEARCH CONTRACTS KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66103 481108830 501(c)(3) 149611 RESEARCH CONTRACTS MAYO CLINIC PO BOX 860334 MINNEAPOLIS MN 55468 416011702 501(C)(3) 107632 RESEARCH CONTRACTS 15 ALBERT SZENT-GYORGYI PRIZE 1 25000 PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. X X X X false false false false false false false false false FRANKLIN C SALISBURY JR CHIEF EXECUTIVE OFFICER 313852 0 53000 0 16338 0 383190 0 0 0 SUJUAN BA PRESIDENT/COO 300778 0 53000 0 12788 0 366566 0 0 0 YI WANG CHIEF SCIENCE OFFICER 189686 0 28398 0 2325 0 220409 0 0 0 X 3 24840 stock market value X CHEMICALS AND EQUIPMENT 5 560028 FMV X SUPERCOMPUTER TIME RIGHTS 1 30000 DISCOUNTED FMV false true false PART III, LINE 4A - CANCER RESEARCH PROGRAM ACCOMPLISHMENTS: HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS With support from our generous donors, NFCR-funded scientists have made numerous remarkable advances in the fight against cancer. Their research encompasses a wide variety of fields, many of which could ultimately lead to a cure for this deadly disease. Below are highlights of research accomplishments made by NFCR-funded scientists over the past year. Prevention ---------- Selenium for Immune Health and Cancer Prevention: A well-balanced diet contributes significantly to the maintenance of good health, and NFCR-sponsored researchers have been investigating the links between nutrition and cancer prevention for decades. Their latest research publications have focused on the role of selenium, a nutrient found in certain nuts, fruits, and multi-micronutrient supplements. The body incorporates selenium into specialized compounds and proteins that are not only critical for chemoprevention of cancer, but can also improve the function of immune cells to fight infection or even cancer, directly. While there is no need for healthy people without a deficiency to supplement their selenium intake, for those fighting infections or cancer it may be beneficial. Helmut Sies, M.D. Detection --------- New Biomarkers for Early Detection of Ovarian Cancer: Since ovarian cancer usually causes few symptoms before progress to the deadly late stages, it is rarely detected early, earning the name "the silent killer". In cases where it is detected early, however, the cure rate is very high over 92% of women survive 5 years or longer after diagnosis. NFCR scientists are developing new tests that can greatly increase early detection of ovarian cancer, saving patients lives. This includes a new immunoassay to evaluate autoantibodies against TP53 mutant proteins. Its our hope that a strategy combining this new test with existing biomarkers will greatly increase the specificity of ovarian cancer screening, making life-saving tests available to more women. Robert Bast, M.D. Capturing Circulating Tumor Cells: NFCR scientists continue to refine the CTC-iChip, the revolutionary blood test that can capture extraordinarily rare circulating tumor cells from a patients blood sample one tumor cell per billion blood cells expanding its use to patients with breast, lung, and a variety of other cancer types. This test may offer a new tool to rapidly detect and effectively treat invasive cancers in early stages. With further refinements, we hope that this test could one day be used as part of a routine screening for cancer survivors, to detect the return of cancer long before it would otherwise be detected with current procedures. Daniel Haber, M.D., Ph.D. Treatment --------- Making the Connections in Tumor Genetics: There are many different cancer types, but all are connected through the fundamental building blocks of genetics. NFCR-supported scientists have made great strides in deepening our understanding of tumor genetics, for the benefit of patients. This year, as part of an international effort, NFCR scientists discovered that many patients with gastric cancer have mutations in the well-known BRCA2 gene, which means they may benefit from existing treatments for breast cancer. They also discovered a key genetic factor that makes brain tumors resistant to treatment, as well as a genetic biomarker that will help doctors choose whether to pursue early, aggressive treatments for the patients with endometrial cancer who are most likely to benefit. Wei Zhang, Ph.D. New Platform for Rapid Drug Screening: Drug resistance is a devastating problem for cancer patients. Although many genetically targeted drugs are effective at first, they almost always stop working as cancers can activiate so-called "escape pathways". A team of NFCR-supported researchers has developed a new platform that can rapidly identify effective drug combinations for certain lung cancer patients whose tumors have stopped responding to targeted therapy. Using advanced genetics, this team is designing more effective drug combinations to both attack cancer cells and eliminate potential escape pathways. Alice Shaw, M.D., Ph.D. Improving Surgeries for Breast and Skin Cancer: For many breast and skin cancer patients, surgery is the first and most effective treatment option. Too often, however, patients leave the hospital after surgery, only to learn that further testing revealed traces of cancer in the margins of their tissue. NFCR scientists are developing a new advanced molecular imaging probe, which allows surgeons to see within minutes whether the margins of breast cancer lumpectomies are cancer-free, greatly reducing the need to call patients back for a second surgery. James Basilion, Ph.D. Revolutionary Adoptive Immunotherapy: For many years, NFCR scientists have been hard at work developing a revolutionary new approach to treating cancer called adoptive immunotherapy. In this technique, patients own immune cells are collected, and using genetic engineering they are "trained" to recognize and and destroy cancer cells. Early in 2015 a new company, Ziopharm, was launched to translate this immunotherapy approach into new treatments for patients in clinics across the U.S. This is an excellent example of NFCRs unique and successful approach to funding cancer research, the culmination of more than a decade of continuous support that will have a huge impact in the lives of cancer patients. Laurence Cooper, M.D., Ph.D. In Clinics Now in 2015 ---------------------- New Front-line Treatment for Lung Cancer In July 2015, the FDA approved the drug Iressa as front-line treatment for patients with non-small cell lung cancer (NSCLC). The approval is extended to only those patients whose tumors contain specific mutations originally identified by an NFCR scientist that make the drug especially effective. NFCR scientists are leading the way in personalized medicine, helping new treatments reach the patients who will benefit the most. Daniel Haber, M.D., Ph.D. New Research Program in 2015 ---------------------------- Thanks to the commitment of our donors, we are able to not only provide critical research funding for our existing programs, but to also advance an entirely new research program that could change the tide against the deadliest brain cancer - glioblastome (GBM). Unprecedented Global Effort to Defeat Glioblastoma GBM AGILE: NFCR has partnered with other international organizations to launch an unprecedented new clinical trial to defeat glioblastoma, the deadliest form of brain cancer. This project is truly global, with over 150 participants from more than 40 leading cancer institutions across three continents. It implements a new generation of clinical trial called an "adaptive trial" - which allows patients to be enrolled more quickly, receive treatment with multiple anti-cancer drugs simultaneously, and does not require years of follow-up to determine whether a new experimental treatment is beneficial. This revolutionary "Adaptive, Global, Innovative Learning Environment" offers a more "AGILE" approach to combat this deadly disease. On November 12, 2015, the group announced the formation of this unprecedented international coalition and its plan to enroll patients by mid-2016. PART III, LINE 4B-CANCER EDUCATION TO THE PUBLIC PROGRAM ACCOMPLISHMENTS: NFCR provides the public with free publications containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message sent to tens of millions of families has helped to assure that fewer of today's healthy individuals will get cancer and more of today's cancer patients will become tomorrow's cancer survivors. Our public education materials include early cancer detection guide, a Childhood Cancer Chart, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. PART VI, SECTION A, LINE 2 - DIRECTORS/OFFICERS WITH FAMILY RELATIONSHIPS: FRANKLIN SALISBURY, CEO, AND SUJUAN BA, PRESIDENT/COO, ARE HUSBAND AND WIFE. PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================= 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBERS' COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFICIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILING DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLY IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================== 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION ARRANGEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. PART VI, SECTION C, LINE 19-AVAILABILITY OF DOCUMENTS, POLICIES AND F/S: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDTAION'S WEBSITE. FUND FOR INHERITED DISEASE RESEARCH INC 4600 EAST-WEST HIGHWAY 525 BETHESDA MD 20814 470852643 CANCER RESEAR PA 501(C)3 509(A)(3) NFCR false CONSORTIUM FOR CLINICAL DIAGNOSTICS 4600 EAST-WEST HIGHWAY 525 BETHESDA MD 20814 371473821 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR false RESEARCH FOR A CURE 4600 EAST-WEST HIGHWAY 525 BETHESDA MD 20814 010744146 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR false false false true false false false false false false false false false false true false false false false NFCR WESTERN CHAPTER C 380000 CASH NFCR MID-ATLANTIC CHAPTER C 215000 CASH